Emcure Pharmaceuticals is a technology-driven biopharmaceutical company that focuses on developing, manufacturing, and marketing a diverse range of pharmaceutical products across various therapeutic areas. The company emphasizes its commitment to research and development, which is supported by a team of approximately 500 qualified scientists. Emcure's R&D efforts are particularly notable in the field of Active Pharmaceutical Ingredients (APIs), where they have pioneered advancements in chiral chemistry, successfully developing and marketing multiple chiral molecules that offer improved efficacy and safety profiles compared to their non-chiral counterparts. This focus on complex generic APIs, including those for oncology and antiretroviral treatments, showcases Emcure's dedication to delivering high-quality, cost-effective healthcare solutions.

In addition to its API research, Emcure Pharmaceuticals has established specialized facilities for the production of various pharmaceutical products, including immunosuppressants and iron-based medications. The company employs sophisticated analytical techniques and customized reactor designs to ensure the safety and efficacy of its complex generics. Emcure's innovative approach extends to the development of biotherapeutics and mRNA vaccines, reflecting its commitment to addressing contemporary health challenges. With a presence in over 70 countries, Emcure Pharmaceuticals continues to leverage its technological capabilities to enhance patient care and contribute to global health initiatives.

United States

Emcure Pharmaceuticals Ltd. (EPL) is an Indian pharmaceutical company headquartered in Pune engaged in developing, manufacturing and globally marketing a broad range of pharmaceutical products across several major therapeutic areas. Established in 1981, EPL is ranked as the 11th largest company in Indian Pharmaceutical Market as per AWACS MAT Feb'24 data.

Emcure Pharmaceuticals

Company Details